CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Teriparatide 20 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00759772
NCT00759772Phase 2Completed
CompareCT.gov

The Role of PTH in Low Bone Mass in Anorexia Nervosa

Massachusetts General Hospital·interventional·Posted Sep 25, 2008·Updated May 11, 2017

In Brief

A Phase 2 clinical trial evaluating Placebo and Teriparatide for Anorexia Nervosa and Osteoporosis. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa, or disordered eating. Women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. We are investigating whether a hormone that is naturally produced by the human body -- parathyroid hormone (PTH) -- can help strengthen the bones of women with anorexia nervosa.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa, Osteoporosis
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2008
Enrollment StartSep 1, 2008
Primary CompletionFeb 22, 2016
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 17.8 years ago

Interventions

Placebodrug

sc daily for 6 months

Teriparatidedrug

20 mcg sc daily for 6 months